Loading clinical trials...
Loading clinical trials...
A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
Conditions
Interventions
Ceralasertib
Locations
18
United States
Research Site
Duarte, California, United States
Research Site
Los Angeles, California, United States
Research Site
San Francisco, California, United States
Research Site
Tampa, Florida, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Baltimore, Maryland, United States
Start Date
December 1, 2020
Primary Completion Date
February 18, 2025
Completion Date
February 18, 2025
Last Updated
August 29, 2025
NCT06815575
NCT05514132
NCT05508334
NCT04907851
NCT03518606
NCT04434482
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions